Evidence map›Paper›PMID 42794994›Full record

ArticleCancers2026

Standardized Upstream Processing of Ovarian Cancer Surgical Specimens for TIL-Oriented Cellular Workflows.

Anna Biernacka, Joanna Kacperczyk-Bartnik, Ewa Witkowska, Julia Foremniak, Mariusz Bidziński, Paweł Derlatka, Justyna Marynowska

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna BiernackaDepartment of Regenerative Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0009-0008-9168-2700
Joanna Kacperczyk-BartnikDepartment of Gynecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-2539-3894
Ewa WitkowskaDepartment of Regenerative Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0009-0001-3484-416X
Julia ForemniakDepartment of Regenerative Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0009-0005-4036-0064
Mariusz BidzińskiDepartment of Gynecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Paweł DerlatkaDepartment of Gynecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0001-9406-6868
Justyna MarynowskaDepartment of Regenerative Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0009-0000-9660-7496

Funding

Agencja Badań Medycznych 2024/ABM/03/KPO/KPOD.07.07-IW.07-0180/24-00
6 · The paper itself

Abstract

backgroundFresh ovarian cancer tissue is a demanding starting material for cellular workflows, particularly when the aim is to obtain tumor-derived suspensions suitable for further TIL-oriented procedures. In this study, we evaluated post-isolation cell concentration and viability in ovarian cancer specimens processed according to a standardized mechanical-enzymatic protocol.

methodsBiological material was collected from 24 patients undergoing routine surgery for ovarian cancer or suspected advanced ovarian malignancy. After macroscopic assessment and exclusion of extensively necrotic tissue, 19 specimens were included in the final analysis. The cohort was dominated by high-grade serous ovarian carcinoma, which accounted for 15 of 19 analyzed cases. Tissue specimens varied markedly in mass, with a median processed tissue weight of 2.05 g and a range from 0.11 to 14.93 g.

resultsThe median final cell concentration was 8.10 × 10

conclusionsThese findings show that standardized processing of ovarian cancer surgical specimens can generate cell suspensions suitable for post-isolation quality assessment, even when the input material is highly variable. The present study focused on early post-isolation quality-control readouts obtained after tumor dissociation and did not evaluate TIL expansion capacity, detailed TIL phenotype, or antitumor function. The wide range of final cell concentrations underlines the biological and practical heterogeneity of ovarian cancer tissue and supports the need for careful reporting of early tissue-processing parameters in TIL-oriented workflows.

Indexed as

cell viabilitygentleMACShigh-grade serous ovarian cancerovarian cancertissue processingtumor-infiltrating lymphocytes

Identifiers

PMID42794994
PMCPMC13605654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.